CA2724603A1 - Pyrazolospiroketone acetyl-coa carboxylase inhibitors - Google Patents

Pyrazolospiroketone acetyl-coa carboxylase inhibitors Download PDF

Info

Publication number
CA2724603A1
CA2724603A1 CA2724603A CA2724603A CA2724603A1 CA 2724603 A1 CA2724603 A1 CA 2724603A1 CA 2724603 A CA2724603 A CA 2724603A CA 2724603 A CA2724603 A CA 2724603A CA 2724603 A1 CA2724603 A1 CA 2724603A1
Authority
CA
Canada
Prior art keywords
compound
composition
obesity
animals
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2724603A
Other languages
English (en)
French (fr)
Inventor
Kevin Daniel Freeman-Cook
Brian Matthew Samas
Scott Joseph Bader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of CA2724603A1 publication Critical patent/CA2724603A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2724603A 2008-05-28 2009-05-18 Pyrazolospiroketone acetyl-coa carboxylase inhibitors Abandoned CA2724603A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5665208P 2008-05-28 2008-05-28
US61/056,652 2008-05-28
US5868908P 2008-06-04 2008-06-04
US61/058,689 2008-06-04
US17111209P 2009-04-21 2009-04-21
US61/171,112 2009-04-21
PCT/IB2009/005659 WO2009144555A1 (en) 2008-05-28 2009-05-18 Pyrazolospiroketone acetyl-coa carboxylase inhibitors

Publications (1)

Publication Number Publication Date
CA2724603A1 true CA2724603A1 (en) 2009-12-03

Family

ID=40974463

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2724603A Abandoned CA2724603A1 (en) 2008-05-28 2009-05-18 Pyrazolospiroketone acetyl-coa carboxylase inhibitors

Country Status (5)

Country Link
US (1) US20110009443A1 (cg-RX-API-DMAC7.html)
EP (1) EP2297164A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011521940A (cg-RX-API-DMAC7.html)
CA (1) CA2724603A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009144555A1 (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5435592B2 (ja) 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
ES2444543T3 (es) 2009-11-10 2014-02-25 Pfizer Inc Inhibidores de la N1-pirazoloespirocetona acetil-CoA carboxilasa
KR101455917B1 (ko) 2010-03-19 2014-11-03 화이자 인코포레이티드 2,3-디히드로-1h-인덴-1-일-2,7-디아자스피로[3.5]노난 유도체 및 그렐린 수용체의 길항제 또는 역 작용제로서의 그 용도
US9006450B2 (en) * 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
EP2621493B1 (en) 2010-09-30 2016-08-17 Pfizer Inc N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
CN104774205A (zh) 2010-10-29 2015-07-15 辉瑞大药厂 N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂
JP5657174B2 (ja) 2011-04-22 2015-01-21 ファイザー・インク アセチルＣｏＡカルボキシラーゼ阻害剤として使用するためのピラゾロスピロケトン誘導体
CA2841757A1 (en) 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
BR112014000288A2 (pt) 2011-07-22 2017-01-10 Pfizer moduladores do receptor de glucagon de quinolinila
EP2751116B1 (en) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
BR112014011254A2 (pt) 2011-11-11 2017-05-16 Pfizer 2-tiopirimidinonas
SG11201405477XA (en) 2012-04-06 2014-11-27 Pfizer Diacylglycerol acyltransferase 2 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2013164730A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
CA2882389A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014091352A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
EP2935282A1 (en) 2012-12-19 2015-10-28 Pfizer Inc. CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
JP2016507551A (ja) 2013-02-13 2016-03-10 ファイザー・インク ヘテロアリール置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
BR112016004118A2 (pt) 2013-09-12 2017-10-17 Pfizer uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
ES2665153T3 (es) 2013-10-09 2018-04-24 Pfizer Inc. Antagonistas del receptor EP3 de prostaglandina
TR201809388T4 (tr) 2014-03-17 2018-07-23 Pfizer Metabolik ve ilişkili hastalıkların tedavisinde kullanılmaya yönelik diasilgliserol asiltransferaz 2 inhibitörleri.
HUE044180T2 (hu) 2014-04-04 2019-10-28 Pfizer Biciklusos kondenzált heteroaril- vagy aril-vegyületek és ezek alkalmazása IRAK4 inhibitorokként
PE20170327A1 (es) 2014-04-10 2017-04-21 Pfizer 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4d] [1,3] TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
EP3194367B1 (en) * 2014-09-17 2021-08-18 Boehringer Ingelheim International GmbH Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes
WO2016092413A1 (en) 2014-12-10 2016-06-16 Pfizer Inc. Indole and indazole compounds that activate ampk
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
BR112017022340A2 (pt) 2015-05-05 2018-07-10 Pfizer 2-tiopirimidinonas
JP2018516254A (ja) 2015-05-29 2018-06-21 ファイザー・インク バニン１酵素の阻害薬としての新規なヘテロ環化合物
UA125334C2 (uk) 2015-06-17 2022-02-23 Пфайзер Інк. Трициклічні сполуки та їх застосування як інгібіторів фосфодіестерази
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
JP2018527337A (ja) 2015-08-13 2018-09-20 ファイザー・インク 二環式縮合ヘテロアリールまたはアリール化合物
JP6804524B2 (ja) 2015-08-27 2020-12-23 ファイザー・インク Ｉｒａｋ４モジュレーターとしての二環式縮合ヘテロアリールまたはアリール化合物
WO2017037567A1 (en) 2015-09-03 2017-03-09 Pfizer Inc. Regulators of frataxin
EP3353183A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3]thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl]amides
EP3353182A1 (en) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
EP3353174A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
CU24540B1 (es) 2015-12-29 2021-08-06 Pfizer 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CN109328193A (zh) 2016-04-19 2019-02-12 尤瑞卡有限公司 肽-低聚脲折叠体化合物及其使用方法
US10906888B2 (en) 2016-07-14 2021-02-02 Pfizer Inc. Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
WO2019133445A1 (en) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles as inhibitors of vanin-1
CN112955147A (zh) 2018-08-31 2021-06-11 辉瑞公司 用于治疗nash/nafld和相关疾病的组合
WO2020102575A1 (en) 2018-11-16 2020-05-22 Inception Ibd, Inc. Heterocyclic aminothiazoles and uses thereof
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
WO2020234726A1 (en) 2019-05-20 2020-11-26 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
CN110922372A (zh) * 2019-11-04 2020-03-27 天津大学 达格列净的氨基酸共晶物及其制备方法
PH12022552056A1 (en) 2020-02-07 2024-02-12 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
AU2021275292A1 (en) * 2020-05-21 2022-12-15 Shionogi & Co., Ltd. Pharmaceutical for treating fatty liver diseases
JP2025509281A (ja) 2022-03-09 2025-04-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2614963C (en) * 2005-07-19 2014-10-07 Merck & Co., Inc. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
ATE552262T1 (de) * 2006-11-29 2012-04-15 Pfizer Prod Inc Spiroketone als inhibitoren von acetyl-coa- carboxylase

Also Published As

Publication number Publication date
EP2297164A1 (en) 2011-03-23
WO2009144555A1 (en) 2009-12-03
US20110009443A1 (en) 2011-01-13
JP2011521940A (ja) 2011-07-28
WO2009144555A8 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
CA2724603A1 (en) Pyrazolospiroketone acetyl-coa carboxylase inhibitors
US11673890B2 (en) N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US8318762B2 (en) Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
DK2632925T3 (en) N1 / N2-lactam acetyl-CoA carboxylase inhibitors
AU2012245996B2 (en) Pyrazolospiroketone derivatives for use as acetyl-CoA carboxylase inhibitors
US20140288111A1 (en) N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
US20120225900A1 (en) N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20131101